Could the very treatments designed to rescue the mind from severe depression also be quietly restructuring the physical framework of our bones? A groundbreaking review reveals that ketamine and its enantiomers directly interface with the cellular demolition and construction crews regulating skeletal density.
This research demonstrates that low-dose arketamine can shield bone-building osteoblasts from stress-induced damage, whereas high anesthetic doses can trigger cell toxicity and impair healing. Furthermore, it highlights the current reliance on chemical biomarkers rather than long-term bone density scans. Tune in to discover why your mental health therapy might be sending systemic ripples all the way down to your skeleton.
Resources:
Louka, P., Pitsillides, A., Koumas, M., Papacharalambous, C., Sophocleous, A., & Zanos, P. (2026). From depression to bone health: Examining the skeletal effects of classical and rapid-acting antidepressants. International Journal of Neuropsychopharmacology, Article pyag044. https://doi.org/10.1093/ijnp/pyag044
Podden och tillhörande omslagsbild på den här sidan tillhör
Talking Ketamine. Innehållet i podden är skapat av Talking Ketamine och inte av,
eller tillsammans med, Poddtoppen.
